By Ron Lanton III, Esq. | Lanton Strategies International B.V.
For a European biotechnology company, the decision to enter the United States can be as consequential as the decision to develop a new medicine. Management must determine how the product will be commercialized, how it will reach patients and whether the company has the resources to support a U.S. launch.
These questions deserve attention before regulatory approval, particularly when a company is negotiating a licensing transaction, raising capital or deciding whether to establish its own American operations.
Decide How the Company Will Enter the Market
A European company may license U.S. commercial rights to a partner, retain those rights and build its own operations, or pursue a combination of the two. Each approach has different consequences for financing, staffing, control over commercialization and the company's ability to participate in future revenue.
Management should establish what it expects from a U.S. partner before negotiating financial terms. Responsibilities for pricing, market access, distribution, patient support and post-launch investment can be just as important as upfront payments and royalties. A company should understand which decisions it will retain and which it will leave to its partner.
Understand Who Will Pay for the Medicine
The United States has multiple public and private coverage arrangements rather than a single national reimbursement system. A product's route to patients can differ substantially depending on whether it is administered in a physician's office, dispensed through a pharmacy or provided in a hospital.
Biotechnology executives should determine which reimbursement channels are relevant to their products, how coverage decisions affect demand and how payer or pharmacy benefit manager requirements may influence commercial performance. Those findings should inform launch budgets and revenue projections.
Plan Distribution Before Making Commercial Commitments
Distribution decisions deserve particular attention for specialty medicines. Products that require temperature-controlled storage, specialized administration or ongoing patient support may need a distribution model different from that used for conventional medicines.
Companies should evaluate prospective wholesalers, specialty pharmacies and other commercial partners against their product requirements. They should also consider how contractual responsibilities, access to distribution data and payment terms could affect operations once the product is commercially available.
Account for Government Policy in Investment Decisions
Federal and state policy can affect drug pricing, reimbursement, distribution, manufacturing and international trade. For a European company, changes in American policy can also influence decisions about where to invest and when to introduce a product in different markets.
A U.S. policy assessment should therefore be part of the company's investment analysis. Executives need to distinguish developments that warrant immediate action from those that can be monitored while commercial plans proceed.
Make U.S. Market Entry a Management Decision
Before committing to a U.S. launch, management should be able to explain how the company intends to commercialize the product, how patients will obtain it, who will pay for it and which commercial or policy risks could affect the investment.
These are business decisions that need input from the clinical, regulatory, finance and commercial teams. Addressing them early gives European companies a better basis for evaluating partnerships and determining whether a U.S. investment is commercially justified.
Based in Amsterdam, Lanton Strategies International B.V. advises European pharmaceutical and biotechnology companies on U.S. market entry, pricing, reimbursement, distribution and government affairs. Learn more about our U.S. market entry advisory services for European pharmaceutical and biotechnology companies.
For European biotechnology companies establishing operations in the United States, Lanton, Lanton & Sosa Law PLLC, with offices in Boston and Washington, D.C., provides US legal counsel on corporate formation, regulatory compliance, commercial agreements, employment law, government affairs and outside general counsel services.